0001140361-14-027751.txt : 20140703
0001140361-14-027751.hdr.sgml : 20140703
20140703174600
ACCESSION NUMBER: 0001140361-14-027751
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140701
FILED AS OF DATE: 20140703
DATE AS OF CHANGE: 20140703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 14961670
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
doc1.xml
FORM 4
X0306
4
2014-07-01
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54, RUE LA BOETIE
PARIS
I0
75008
FRANCE
0
0
1
0
Common Stock
2014-07-01
4
P
0
600
285.8900
A
20471841
I
See note
Common Stock
2014-07-01
4
P
0
930
287.0772
A
20472771
I
See note
Common Stock
2014-07-01
4
P
0
543
288.2412
A
20473314
I
See note
Common Stock
2014-07-01
4
P
0
689
289.3166
A
20474003
I
See note
Common Stock
2014-07-01
4
P
0
3513
292.9795
A
20477516
I
See note
Common Stock
2014-07-01
4
P
0
5001
294.2568
A
20482517
I
See note
Common Stock
2014-07-01
4
P
0
11155
295.0946
A
20493672
I
See note
Common Stock
2014-07-01
4
P
0
10463
296.3817
A
20504135
I
See note
Common Stock
2014-07-01
4
P
0
20472
297.2576
A
20524607
I
See note
Common Stock
2014-07-01
4
P
0
8238
298.1332
A
20532845
I
See note
Common Stock
2014-07-01
4
P
0
16683
299.1603
A
20549528
I
See note
Common Stock
2014-07-01
4
P
0
18074
300.2167
A
20567602
I
See note
Common Stock
2014-07-01
4
P
0
39530
301.2295
A
20607132
I
See note
Common Stock
2014-07-01
4
P
0
11932
302.3760
A
20619064
I
See note
Common Stock
2014-07-01
4
P
0
42419
303.2385
A
20661483
I
See note
Common Stock
2014-07-01
4
P
0
22158
304.0121
A
20683641
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). The shares were purchased pursuant to a plan intended to comply with Rule 10b5-1(c)(1)(i) under the Exchange Act, entered into with a broker on June 27, 2014.
Purchase prices range from $285.55 to $286.25 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 17,884,089 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuers Board of Directors.
Purchase prices range from $286.69 to $287.50 per share, inclusive..
Purchase prices range from $287.74 to $288.72 per share, inclusive.
Purchase prices range from $289.00 to $289.53 per share, inclusive.
Purchase prices range from $292.50 to $293.38 per share, inclusive.
Purchase prices range from $293.67 to $294.64 per share, inclusive.
Purchase prices range from $294.68 to $295.53 per share, inclusive.
Purchase prices range from $295.70 to $296.67 per share, inclusive.
Purchase prices range from $296.72 to $297.69 per share, inclusive.
Purchase prices range from $297.72 to $298.68 per share, inclusive.
Purchase prices range from $298.73 to $299.72 per share, inclusive.
Purchase prices range from $299.73 to $300.72 per share, inclusive.
Purchase prices range from $300.73 to $301.70 per share, inclusive.
Purchase prices range from $301.79 to $302.76 per share, inclusive.
Purchase prices range from $302.80 to $303.79 per share, inclusive.
Purchase prices range from $303.80 to $304.41 per share, inclusive.
/s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law
2014-07-03